Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04081688 | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | terminated | Phase 1 | 16 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04836429 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 1 | 42 | Prelude TherapeuticsINDUSTRY | 6 | Feb 2, 2026 | clinicaltrials |
| NCT03436056 | PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients(PRIMING) | terminated | Phase 1 | 2 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05302817 | Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI | terminated | Phase 1 | 9 | Xemed LLCINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03780725 | This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091 | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04585815 | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) | terminated | Phase 1 / Phase 2 | 34 | PfizerINDUSTRY | 4 | Jan 9, 2026 | clinicaltrials |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | terminated | Phase 1 | 250 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 5 | Jan 9, 2026 | clinicaltrials |
| NCT05676749 | C-TIL051 in Non-Small Cell Lung Cancer | terminated | Phase 1 | 1 | AbelZeta Inc.INDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | terminated | Phase 1 / Phase 2 | 5 | Medical University of South CarolinaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 227 | Mythic TherapeuticsINDUSTRY | 7 | Dec 16, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | terminated | Phase 1 | 17 | Bolt Biotherapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04982224 | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | terminated | Phase 1 | 30 | Regeneron PharmaceuticalsINDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05469178 | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | terminated | Phase 1 / Phase 2 | 26 | BerGenBio ASAINDUSTRY | 7 | Oct 29, 2025 | clinicaltrials |
| NCT04543188 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | terminated | Phase 1 | 65 | PfizerINDUSTRY | 3 | Oct 23, 2025 | clinicaltrials |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | terminated | Phase 1 | 29 | Taiho Oncology, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | terminated | Phase 1 | 122 | Novartis PharmaceuticalsINDUSTRY | 9 | Sep 30, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | terminated | Phase 1 | 9 | PfizerINDUSTRY | 3 | Sep 17, 2025 | clinicaltrials |
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma(SABRseq) | terminated | Phase 1 | 13 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05662670 | A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 14 | Suzhou Junjing BioSciences Co., Ltd.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors | terminated | Phase 1 | 44 | Day One Biopharmaceuticals, Inc.INDUSTRY | 2 | Aug 14, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | terminated | Phase 1 | 22 | TransgeneINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | terminated | Phase 1 | 39 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04820023 | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | terminated | Phase 1 / Phase 2 | 45 | Bridge Biotherapeutics, Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT02521051 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 11 | Massachusetts General HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05374538 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 3 | Vitrac Therapeutics, LLCINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Coherus Oncology, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | terminated | Phase 1 | 6 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer(SCope-D1) | terminated | Phase 1 | 18 | AstraZenecaINDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | terminated | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 13, 2025 | clinicaltrials |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | terminated | Phase 1 | 63 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 14 | Allist Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT05911308 | Abequolixron (RGX-104) and Durvalumab in Lung Cancer | terminated | Phase 1 | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | terminated | Phase 1 | 7 | Nouscom SRLINDUSTRY | 3 | Mar 20, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 5, 2026source: clinicaltrials